Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -42.53% is 10% above its 5-year average of -47.47%, near the high end of its 5-year range (-92.08%–-23.94%).
3.57% below its 12-month average of -41.06%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -18.69%.
RETURN ON ASSETS (ROA)
-42.53%
RETURN ON ASSETS (ROA) AVG TTM
-41.06%
RETURN ON ASSETS (ROA) AVG 3Y
-49.54%
RETURN ON ASSETS (ROA) AVG 5Y
-47.47%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-3.57%
CURRENT VS 3Y AVG
+14.15%
CURRENT VS 5Y AVG
+10.41%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-31.92%
vs the sector median at left
Candel Therapeutics, Inc.
Market Cap
$723.18M
Return on Assets (ROA)
-42.53%
TTM Avg
-41.06%
3Y Avg
-49.54%
5Y Avg
-47.47%
Market Cap
$721.69M
Return on Assets (ROA)
-59.88%
TTM Avg
-116.93%
3Y Avg
-132.27%
5Y Avg
-105.87%
Market Cap
$714.37M
Return on Assets (ROA)
-20.44%
TTM Avg
-45.26%
3Y Avg
-91.41%
5Y Avg
-102.66%
Market Cap
$709.65M
Return on Assets (ROA)
2.24%
TTM Avg
3.98%
3Y Avg
2.51%
5Y Avg
4.09%
Market Cap
$702.82M
Return on Assets (ROA)
-41.48%
TTM Avg
-39.59%
3Y Avg
-35.47%
5Y Avg
-52.36%
Market Cap
$747.61M
Return on Assets (ROA)
-32.91%
TTM Avg
-25.26%
3Y Avg
-23.04%
5Y Avg
-20.66%
Market Cap
$694.79M
Return on Assets (ROA)
-18.03%
TTM Avg
-7.81%
3Y Avg
-4.40%
5Y Avg
-1.35%
Market Cap
$693.61M
Return on Assets (ROA)
-36.26%
TTM Avg
-29.77%
3Y Avg
-47.75%
5Y Avg
-50.63%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | $723.18M | -42.53% | -41.06% | -49.54% | -47.47% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $721.69M | -59.88% | -116.93% | -132.27% | -105.87% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $714.37M | -20.44% | -45.26% | -91.41% | -102.66% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.65M | 2.24% | 3.98% | 2.51% | 4.09% |
| Apnimed, Inc. (APMD)vs › | $742.70M | N/A | N/A | N/A | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $702.82M | -41.48% | -39.59% | -35.47% | -52.36% |
| Design Therapeutics, Inc. (DSGN)vs › | $747.61M | -32.91% | -25.26% | -23.04% | -20.66% |
| Cytek Biosciences, Inc. (CTKB)vs › | $694.79M | -18.03% | -7.81% | -4.40% | -1.35% |
| Wave Life Sciences Ltd. (WVE)vs › | $693.61M | -36.26% | -29.77% | -47.75% | -50.63% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $753.02M | -36.55% | -44.22% | -44.22% | -44.22% |
ROA
-42.5%
ROE
-70.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -30.50% |
| 2024-12-31 | -51.63% |
| 2023-12-31 | -92.08% |
| 2022-12-31 | -23.94% |
| 2021-12-31 | -40.50% |
| 2020-12-31 | -46.18% |
| 2019-12-31 | -17.95% |
